The Africa Quinine versus Artesunate in Severe Malaria Trial

Conditions

Malaria Infections and Infestations Malaria

Watson JA, Holmes CC.

2020-05-073 citations

Diagnosis, clinical presentation, and in-hospital mortality of severe malaria in HIV-coinfected children and adults in Mozambique.

Hendriksen IC, Ferro J, Montoya P, Chhaganlal KD, Seni A, Gomes E, Silamut K, Lee SJ, Lucas M, Chotivanich K, Fanello CI, Day NP, White NJ, von Seidlein L, Dondorp AM.

2012-07-0228 citations

10.1093/cid/cis590

Predicting the clinical outcome of severe falciparum malaria in african children: findings from a large randomized trial.

von Seidlein L, Olaosebikan R, Hendriksen IC, Lee SJ, Adedoyin OT, Agbenyega T, Nguah SB, Bojang K, Deen JL, Evans J, Fanello CI, Gomes E, Pedro AJ, Kahabuka C, Karema C, Kivaya E, Maitland K, Mokuolu OA, Mtove G, Mwanga-Amumpaire J, Nadjm B, Nansumba M, Ngum WP, Onyamboko MA, Reyburn H, Sakulthaew T, Silamut K, Tshefu AK, Umulisa N, Gesase S, Day NP, White NJ, Dondorp AM.

2012-03-12142 citations

10.1093/cid/cis034

Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.

Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ, AQUAMAT group.

2010-11-07659 citations

10.1016/s0140-6736(10)61924-1

Interventions

Please note that as of 01/09/10 this trial has reached its target sample size and recruitment has been closed. The trial is now in follow-up. Current information as of 26/01/2009: Patients are rando

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. OptiMal malaria rapid test positive, and 2. Treating physician considers patient to have severe malaria

Exclusion criteria

Exclusion criteria: 1. Patient has received more than or equal to 24 hours of effective treatment with quinine or an artemisinin derivative, or 2. Patient has a known allergy to quinine or an artemisinin derivative

Design outcomes

Primary

Measure	Time frame
In-hospital mortality	—

Secondary

Measure	Time frame
Current information as of 20/04/2010: 1. Neurological sequelae at day 28 after discharge from the hospital 2. Combined in-hospital mortality and neurological sequelae at day 28 after discharge from the hospital Initial information at time of registration: 1. Neurological sequelae 2. Recovery times: 2.1. To localise pain 2.2. To speak 2.3. To sit unsupported 2.4. To eat or breast feed, and 2.5. To discharge from hospital Assessed at discharge.	—

Measure

Time frame

Current information as of 20/04/2010: 1. Neurological sequelae at day 28 after discharge from the hospital 2. Combined in-hospital mortality and neurological sequelae at day 28 after discharge from the hospital Initial information at time of registration: 1. Neurological sequelae 2. Recovery times: 2.1. To localise pain 2.2. To speak 2.3. To sit unsupported 2.4. To eat or breast feed, and 2.5. To discharge from hospital Assessed at discharge.

—

Countries

Congo, Democratic Republic, Gambia, Ghana, Kenya, Mozambique, Nigeria, Rwanda, Tanzania, Uganda

Outcome results

None listed